MX2014010417A - Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. - Google Patents
Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.Info
- Publication number
- MX2014010417A MX2014010417A MX2014010417A MX2014010417A MX2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A MX 2014010417 A MX2014010417 A MX 2014010417A
- Authority
- MX
- Mexico
- Prior art keywords
- booster vaccines
- adjuvanted formulations
- vaccines
- adjuvanted
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención mejora las vacunas TdaP al incluir un agonista de TLR en ellas. Este agonista puede proveer protección más fuerte, protección de duración más larga, y/o puede reducir la cantidad de antígeno que se requiere para lograr una respuesta inmunológica particular.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608398P | 2012-03-08 | 2012-03-08 | |
US201261697730P | 2012-09-06 | 2012-09-06 | |
PCT/EP2013/054672 WO2013132041A2 (en) | 2012-03-08 | 2013-03-08 | Adjuvanted formulations of booster vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014010417A true MX2014010417A (es) | 2014-09-22 |
Family
ID=47843287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010417A MX2014010417A (es) | 2012-03-08 | 2013-03-08 | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
Country Status (9)
Country | Link |
---|---|
US (3) | US9375471B2 (es) |
EP (1) | EP2822581A2 (es) |
JP (5) | JP6345603B2 (es) |
CN (1) | CN104159602B (es) |
AU (1) | AU2013229432A1 (es) |
CA (1) | CA2866406A1 (es) |
MX (1) | MX2014010417A (es) |
RU (1) | RU2014140521A (es) |
WO (1) | WO2013132041A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0923305B1 (pt) | 2008-12-09 | 2019-01-22 | Gilead Sciences Inc | moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
EP2459216B1 (en) * | 2009-09-02 | 2013-10-30 | Novartis AG | Immunogenic compositions including tlr activity modulators |
MX343914B (es) | 2010-09-01 | 2016-11-18 | Glaxosmithkline Biologicals Sa | Adsorcion de inmunopotenciadores en sales metalicas insolubles. |
CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
WO2013030378A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
AU2013229432A1 (en) * | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
KR20160132109A (ko) | 2014-03-26 | 2016-11-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 돌연변이 스태필로코쿠스 항원 |
MA40238A (fr) | 2014-07-11 | 2017-05-17 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
PT3194401T (pt) | 2014-09-16 | 2020-12-23 | Gilead Sciences Inc | Formas sólidas de modulador de recetor tipo toll |
US11344619B2 (en) * | 2016-05-16 | 2022-05-31 | Access To Advanced Health Institute | Formulation containing TLR agonist and methods of use |
WO2020117618A1 (en) * | 2018-12-05 | 2020-06-11 | Sanofi Pasteur Inc. | Pertussis booster vaccine |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3485094D1 (de) | 1983-01-25 | 1991-10-31 | Ciba Geigy Ag | Neue peptidderivate. |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
WO1993018150A1 (en) | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
JP4028593B2 (ja) | 1993-03-23 | 2007-12-26 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物 |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
EP0769018B1 (en) | 1994-07-01 | 2002-12-18 | Chiron Corporation | Helicobacter proteins and vaccines |
DK0793656T3 (da) | 1994-11-24 | 2003-07-21 | Basilea Pharmaceutica Ag | Hidtil ukendte benzyl-pyrimidiner |
DK0909323T3 (da) | 1996-01-04 | 2007-05-21 | Novartis Vaccines & Diagnostic | Helicobacter pylori-bakterioferritin |
GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
JP2002513773A (ja) | 1998-05-07 | 2002-05-14 | コリクサ コーポレイション | アジュバント組成物及びその使用法 |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU2001276619A1 (en) | 2000-07-03 | 2002-01-14 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
DE60228758D1 (de) | 2001-12-12 | 2008-10-16 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia tracheomatis |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
US7273852B2 (en) | 2002-06-13 | 2007-09-25 | The Research Foundation Of The City University Of New York | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
SI1549338T1 (sl) | 2002-10-11 | 2011-04-29 | Novartis Vaccines & Diagnostic | Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi |
US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
SI1644389T1 (sl) | 2003-06-16 | 2011-06-30 | Acad Of Science Czech Republic | Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi |
MXPA05013260A (es) | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
EP1729800A4 (en) | 2004-03-02 | 2008-06-11 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
AU2005235080A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
KR101143060B1 (ko) | 2004-04-05 | 2012-05-08 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
US8758764B2 (en) | 2005-02-18 | 2014-06-24 | Novartis Vaccines And Diagnostics Srl | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
WO2006137953A1 (en) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
CN102526723B (zh) | 2005-06-27 | 2017-07-07 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
WO2007034916A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
JPWO2007034917A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
WO2007034881A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007053455A2 (en) | 2005-10-28 | 2007-05-10 | Vaxinnate Corporation | Polypeptide ligans for toll-like receptor 4 (tlr4) |
EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
CA2633142A1 (en) | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
EP1987030B1 (en) | 2006-02-17 | 2011-11-09 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
WO2007109812A2 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
JP5356228B2 (ja) | 2006-07-07 | 2013-12-04 | ギリアード サイエンシーズ, インコーポレイテッド | toll様レセプター7の調節因子 |
GB0616306D0 (en) * | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
NZ575273A (en) | 2006-09-07 | 2012-02-24 | Glaxosmithkline Biolog Sa | Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid |
ES2397714T3 (es) | 2006-10-12 | 2013-03-08 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende un adyuvante de emulsión de aceite en agua |
WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
AR065372A1 (es) | 2007-02-19 | 2009-06-03 | Smithkline Beecham Corp | Derivados de purina |
PE20081887A1 (es) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
EP2155743B1 (en) | 2007-05-08 | 2012-08-29 | AstraZeneca AB | Imidazoquinolines with immuno-modulating properties |
US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
ATE553774T1 (de) | 2007-10-19 | 2012-05-15 | Novartis Ag | Meningokokkenimpfstoffformulierungen |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
US8092813B1 (en) | 2007-12-28 | 2012-01-10 | Novartis Ag | Polychlorinated biphenyls and squalene-containing adjuvants |
NZ588191A (en) | 2008-03-03 | 2012-06-29 | Irm Llc | Compounds and compositions as tlr activity modulators |
EA023556B1 (ru) | 2008-03-24 | 2016-06-30 | 4ЭсЦэ АГ | 1,2-дизамещенные-4-аминоимидазохинолины |
EP2303236A4 (en) | 2008-07-01 | 2012-09-26 | Univ Emory | SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS |
ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
KR101443064B1 (ko) | 2008-08-28 | 2014-09-19 | 노파르티스 아게 | 과-생산 효모 유래 스쿠알렌의 제조 |
TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
BRPI0923305B1 (pt) | 2008-12-09 | 2019-01-22 | Gilead Sciences Inc | moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
EP2398821B1 (en) | 2009-02-17 | 2017-08-30 | GlaxoSmithKline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
NZ595689A (en) | 2009-04-14 | 2014-03-28 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
RU2011154363A (ru) | 2009-06-01 | 2013-07-20 | Новартис Аг | Комбинации клад rrgb пневмококков |
CN102762226A (zh) | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
CN102596240B (zh) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
EP2459216B1 (en) | 2009-09-02 | 2013-10-30 | Novartis AG | Immunogenic compositions including tlr activity modulators |
WO2011057267A1 (en) | 2009-11-09 | 2011-05-12 | National Jewish Health | Vaccine composition |
PL2356983T3 (pl) | 2009-12-03 | 2013-08-30 | Novartis Ag | Cyrkulacja komponentów w czasie homogenizacji emulsji |
PL2343052T3 (pl) | 2009-12-03 | 2013-11-29 | Novartis Ag | Hydrofilowa filtracja podczas produkcji adiuwantów do szczepionek |
MX340263B (es) | 2009-12-03 | 2016-07-04 | Novartis Ag * | Disposicion de camaras de interaccion y contrapresion para la microfluidizacion. |
WO2011119759A1 (en) | 2010-03-23 | 2011-09-29 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
EP2558069A1 (en) | 2010-04-13 | 2013-02-20 | Novartis AG | Benzonapthyridine compositions and uses thereof |
PL2569267T5 (pl) | 2010-05-12 | 2017-10-31 | Novartis Ag | Ulepszone sposoby otrzymywania skwalenu |
GB201009673D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009671D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
MX343914B (es) | 2010-09-01 | 2016-11-18 | Glaxosmithkline Biologicals Sa | Adsorcion de inmunopotenciadores en sales metalicas insolubles. |
WO2012082914A1 (en) | 2010-12-14 | 2012-06-21 | Novartis Ag | Flow cytometry analysis of materials adsorbed to metal salts |
CN103533954B (zh) * | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
WO2013030378A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
LT2822947T (lt) | 2012-03-07 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Tlr7 agonisto arginino druskos |
US20150132339A1 (en) | 2012-03-07 | 2015-05-14 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
AU2013229465A1 (en) | 2012-03-07 | 2014-09-04 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
AU2013229432A1 (en) | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
WO2014037472A1 (en) | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
CA2888721A1 (en) | 2012-10-25 | 2014-05-01 | Glaxosmithkline Biologicals Sa | Nicotinamide as adjuvant |
-
2013
- 2013-03-08 AU AU2013229432A patent/AU2013229432A1/en not_active Abandoned
- 2013-03-08 RU RU2014140521A patent/RU2014140521A/ru not_active Application Discontinuation
- 2013-03-08 JP JP2014560382A patent/JP6345603B2/ja active Active
- 2013-03-08 US US13/790,948 patent/US9375471B2/en active Active
- 2013-03-08 WO PCT/EP2013/054672 patent/WO2013132041A2/en active Application Filing
- 2013-03-08 MX MX2014010417A patent/MX2014010417A/es active IP Right Grant
- 2013-03-08 CA CA2866406A patent/CA2866406A1/en not_active Abandoned
- 2013-03-08 CN CN201380012817.4A patent/CN104159602B/zh active Active
- 2013-03-08 EP EP13708155.0A patent/EP2822581A2/en not_active Withdrawn
-
2016
- 2016-05-24 US US15/163,592 patent/US9931399B2/en active Active
-
2017
- 2017-05-15 JP JP2017096343A patent/JP2017132821A/ja not_active Withdrawn
-
2018
- 2018-02-26 US US15/905,483 patent/US10842868B2/en active Active
- 2018-10-15 JP JP2018194314A patent/JP2019001832A/ja active Pending
-
2021
- 2021-02-02 JP JP2021015094A patent/JP7295895B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045185A patent/JP2023085364A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2822581A2 (en) | 2015-01-14 |
US20180177871A1 (en) | 2018-06-28 |
AU2013229432A1 (en) | 2014-10-16 |
CN104159602A (zh) | 2014-11-19 |
RU2014140521A (ru) | 2016-04-27 |
JP2021088564A (ja) | 2021-06-10 |
US10842868B2 (en) | 2020-11-24 |
CN104159602B (zh) | 2017-10-24 |
US20160263216A1 (en) | 2016-09-15 |
US9375471B2 (en) | 2016-06-28 |
JP7295895B2 (ja) | 2023-06-21 |
CA2866406A1 (en) | 2013-09-12 |
US20130236492A1 (en) | 2013-09-12 |
WO2013132041A3 (en) | 2014-04-10 |
JP2017132821A (ja) | 2017-08-03 |
JP2015509522A (ja) | 2015-03-30 |
JP2019001832A (ja) | 2019-01-10 |
US9931399B2 (en) | 2018-04-03 |
JP2023085364A (ja) | 2023-06-20 |
WO2013132041A2 (en) | 2013-09-12 |
JP6345603B2 (ja) | 2018-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014010417A (es) | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. | |
HK1224178A1 (zh) | 環肽作為蛋白質靶向劑 | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
MX2013002173A (es) | Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos. | |
MX2016007063A (es) | Peptidos terapeuticos. | |
MX352324B (es) | Vacunas multivalentes de nanovehiculos sinteticos. | |
IL237522A0 (en) | Bioconjugates involving adapted antigens and their uses | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
ZA201309386B (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
MX2021004211A (es) | Composiciones vacuna. | |
EP2825196A4 (en) | ADJUVANT AND VACCINE COMPOSITIONS | |
BR112015008417A8 (pt) | composição imunogênica, vacina, e, uso de uma composição imunogênica | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
EP3010340A4 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
MX2014006630A (es) | Vacuna a base toxina clostridium difficile. | |
TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
HK1254514A1 (zh) | 用於增强疫苗接種免疫反應的方法及組合物 | |
CL2015001618A1 (es) | Adyuvante de vacunación, preparación y vacunas que lo contienen | |
MX2015015428A (es) | Eliminacion de riesgo de narcolepsia en vacunas contra influenza. | |
WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing | |
EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
PL3077512T3 (pl) | Immunogenne kompozycje i szczepionki pochodzące od bakteryjnych białek receptora powierzchniowego |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA |
|
FG | Grant or registration |